AARTIPHARMAarti Pharmalabs Limited
Pharma · Drug Manufacturers - Specialty & Generic · NSE · as of 2026-09-11 (delayed ~30 min in market hours)
Aarti Pharmalabs Limited, together with its subsidiaries, manufactures and sells active pharmaceutical ingredients, pharmaceutical intermediates, and xanthine derivatives in India and internationally. The company offers active pharmaceutical ingredients for various therapeutic areas, such as cardiovascular, anti-asthmatic, anti-cancer, anti-coagulant, anti-diabetic, arthritis, central nervous system agent, skincare, overactive bladder, calcimimetic, decongestant, anti-thalassaemic, analgesic, and ophthalmologic medications. It also provides contract development and manufacturing services for drug substance projects. In addition, the company offers intermediates; xanthine derivatives, including caffeine, theophylline anhydrous, aminophylline, etophylline, and theophylline; and acid and allied products, including sulphuric acid, sulphur trioxide, oil, dimethyl sulphate, diethyl sulphate, and sodium vinyl sulfonate. The company was formerly known as Aarti Organics Limited. Aarti Pharmalabs Limited was incorporated in 2019 and is headquartered in Mumbai, India.
Price & Volume
Loading chart…
Key Ratios
“—” means the figure isn't meaningful or isn't published for this company: ROE and Debt/Equity are undefined when shareholder equity is negative (check P/B — negative means negative equity), and DII/MF holding splits aren't provided by our current data source.
Active Pattern Signals
None of the 16 pattern scanners currently detects a setup on AARTIPHARM — signals appear here automatically when one forms (checked on every data refresh). The Trade Plan on the right always provides stop-loss and target levels regardless.
The picture
- • Debt/Equity: 0.37
- • Valuation vs sector: P/E 43.0 vs sector 40.5
- • RSI: 52
- • Price vs SMA50: above
- • Price vs SMA200: above
- • 3-month return: +29.3%
Bull case
- • Debt/Equity: 0.37
- • Valuation vs sector: P/E 43.0 vs sector 40.5
- • RSI: 52
- • Price vs SMA50: above
Bear case
- • Revenue growth: 3.3% YoY
- • Profit growth: -30.8% YoY
- • MACD: bearish
- • Price vs EMA21: below
Key risks
- • Weak fundamentals — technical strength may not sustain
- • Revenue growth: 3.3% YoY
- • Profit growth: -30.8% YoY
Algorithmic analysis for research only — not SEBI-registered investment advice.
Trade Plan
Stop = 20-day support with a 2.5×ATR risk cap (ATR ₹33.46). Levels recompute on every data refresh. Position sizing and execution are yours — this is analysis, not advice.